Serum levels of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy

Oncology Research

Volumn 16, Issue 1, 2006, Pages 49-54

  Izycki, Tomasz ^a,b   Chyczewska, Elzbieta ^a   Naumnik, Wojciech ^a   Ossolinska, Maria ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b NONE   (Poland)

Author keywords

Chemotherapy; IGF I; IGFBP 3; Lung cancer

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; SOMATOMEDIN BINDING PROTEIN;

ADENOCARCINOMA; ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CONTROL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE;

EID: 33746881087     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006783981251     Document Type: Article

References (22)

1. Wu, X.; Tortolero-Luna, G.; Zhao, H.; et al. Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin. Cancer Res. 9:3356-3361; 2003.
2. Grimberg, A.; Cohen, P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell Physiol. 183:1-9; 2000.
3. Takanami, I.; Imamuma, T.; Hashizume, T.; et al. Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma. J. Surg. Oncol. 61(3):205-208; 1996.
4. Chang, Y. S.; Gong, K.; Sun, S.; et al. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin. Cancer Res. 8(12):3796-3802; 2002.
5. Probst-Hensch, N. M.; Wang, H.; Goh, V. H. H.; et al. Determinants of circulating insulin-like growth factor I and insulin-like growth binding protein 3 concentrations in a cohort of Singapore men and women. Cancer Epidemiol. Biomarkers Prev. 12:739-746; 2003.
6. Lee, K-W.; Cohen, P. Nuclear effects: Unexpected intracellular actions of insulin-like growth factor binding protein-3. J. Endocrinol. 175:33-40; 2002.
7. Minuto, F.; Del Monte, P.; Barreca, A.; et al. Evidence for an increased somatomedin-C/insulin-like growth factor-I content in primary human lung tumors. Cancer Res. 46:985-988; 1986.
8. Lee, D. Y.; Kim, S. J.; Lee, Y. C. Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J. Korean Med. Sci. 14:401-404; 1999.
9. Nakanishi, Y.; Mulshine, J. L.; Kasprzyk, P. G.; et al. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J. Clin. Invest. 82:354-359; 1988.
10. Olchovsky, D.; Shimon, I.; Goldberg, I.; et al. Elevated insulin-like growth factor-1 and insulin-like growth factor binding protein-2 in malignant pleural effusion. Acta Oncol. 41(2):182-187; 2002.
11. Oh, J. C.; Wu, W.; Tortolero-Luna, G.; et al. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol. Biomarkers Prev. 13:748-752; 2004.
12. Pollak, M. Insulin-like growth factor physiology and cancer risk. Eur. J Cancer 36(10):1224-1228; 2002.
13. Fong, K. M.; Sekido, Y.; Gazdar, A. F.; Minna, J. D. Lung cancer? Molecular biology of lung cancer: Clinical implications. Thorax 58:892-900; 2003.
14. Izycki, T.; Chyczewska, E.; Naumnik, W.; et al. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy. Exp. Oncol. 26(4):316-319; 2004.
15. Khandwala, H. M.; McCutcheon, I. E.; Flyvbjerg, A.; Friend, K. E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 21(3):215-244; 2002.
16. Tisi, E.; Lissoni, P.; Rovelli, F.; Mandelli, D.; Barni, S.; Tancini, G. Blood levels of IGF-I in non-small cell lung cancer: Relation to clinical data. Int. J. Biol. Markers 6(2):99-102; 1991.
17. Yu, H.; Spitz, M. R.; Mistry, J.; Gu, J.; Hong, W.; Wu, X. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J. National Cancer Inst. 91(2):151-156; 1999.
18. Spitz, M. R.; Barnett, M. J.; Goodman, G. E.; et al. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: A case-control study nested in the β-carotene and retinol efficacy trial cohort. Cancer Epidemiol. 11:1413-1418; 2002.
19. Wu, X.; Yu, H.; Amos, Ch. I.; Hong, W. K.; Spitz, M. R. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J. Natl. Cancer Inst. 92:737-743; 2000.
20. Rajah, R.; Khare, A.; Lee, P.; Cohen, P. Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. J. Edocrinol. 163:487-494; 1999.
21. Wang, H.; Wan, Y. X.; Zhang, Qk. Significance and expression of insulin-like growth factor 1 and binding protein 3 in serum of patients with lung cancer. Ai Zheng 23:710-714; 2004.
22. Reeve, J. G.; Morgan, J.; Clark, P. M.; Bleehen, N. M. Insulin-like growth factor (IGF) and IGF binding proteins in growth hormone dysregulation and abnormal glucose tolerance in small cell lung cancer patients. Eur. J. Cancer 31A(9):1455-1460; 1995.